Background and objective An elevated heart rate (HR) is an independent risk factor for mortality and morbidity in patients with acute heart failure (HF). The purpose of this study was to evaluate the impact of ivabradine, a selective HR-lowering agent, in patients with cardiogenic shock (CS) complicating ST-elevation acute myocardial infarction (AMI). Methods Patients with post-AMI CS were randomized to standard treatment (SDT, 28 patients) or to standard treatment plus ivabradine (I ? SDT, 30 patients). In the presence of orotracheal intubation (OTI), ivabradine was administered by nasogastric intubation. HR, BP, New York Heart Association (NYHA) class, NT-proBNP, left ventricular ejection fraction (LVEF) and diastolic function (LVDF) were monitored at specific times after the onset of AMI. The primary (surrogate) end-point was the in-hospital halving of plasma NT-proBNP levels. The secondary end-points were cardiovascular death, hospital re-admission for worsening HF, and clinical and haemodynamic improvement. Results Treatment groups were statistically similar with regard to age, gender distribution, cardiovascular risk factors, number of diseased vessels and overall treated lesions, AMI site and occurrence of OTI. In-hospital mortality was double in the SDT group in comparison with the I ? SDT group (14.3 vs. 6.7 %), but the difference was not statistically significant. HR, BP, NT-proBNP and LVEF favorably changed in both groups, but the change was more relevant in the I ? SDT group. LVDF significantly changed only in the I ? SDT group (p \ 0.01). Patients in the I ? SDT group did not experience adverse effects. Conclusion Ivabradine in CS complicating AMI is safe, is associated with a short-term favourable outcome and can be effectively administered by nasogastric intubation.
Introduction
The major cause of in-hospital acute myocardial infarction (AMI) mortality remains acute heart failure (AHF), despite the introduction of modern treatment strategies. An elevated heart rate (HR) in patients with AHF complicating AMI attenuates the decrease in cardiac output but, with impaired left ventricular filling, increases myocardial oxygen consumption and reduces myocardial perfusion time in the ischaemic heart [1] . Thus, elevated HR at rest represents a significant predictor of all-cause and cardiovascular (CV) mortality in the general population and in patients with CV disease. Moreover, patients with AHF and a HR[70 beats/ min have a significantly greater CV mortality and risk for hospital admission than those with a HR\70 beats/min [2] . Recent trials on b-blockers (BBs) in patients with chronic heart failure (CHF) [3] [4] [5] [6] suggest an association between decrease in mortality and magnitude of HR reduction.
Although BBs are clearly beneficial in AMI, they still have disadvantages that limit their benefits [7] and they are usually contraindicated when left ventricular (LV) function is acutely compromised and blood pressure (BP) is very low as in cardiogenic shock (CS). In fact, HR reduction achieved by BBs do not achieve the full potential that might be expected from the increase in the duration of diastole. Their negative lusitropic effects can explain this: considering the diastolic pressure-time integral as the driving force for coronary blood flow, any slowing of isovolumetric ventricular relaxation at any given diastolic duration will impede coronary blood flow [8] . In this situation, selective HR reduction may be advantageous and better tolerated in patients with AHF.
The only selective HR-lowering agent that is currently available for clinical use is ivabradine, a drug that reduces HR selectively by inhibition of the I (f) -channel in the sinus node. Ivabradine provides the opportunity of pure HR reduction, associated with anti-ischaemic efficacy and without any effect on haemodynamics or myocardial contractility [9] . Consequently, the benefits in CHF patients were evaluated in the SHIFT trial, where ivabradine administration was associated with a significant decrease in the composite rate of CV death or HF hospitalisation [10] .
Ivabradine is approved in Europe and the USA for the symptomatic treatment of chronic stable angina pectoris and CHF, alone or in combination with BBs. Its use in AHF or CS is not customary: a small study reported clinical benefits in ten patients with acute decompensated HF [11] , but there are no randomized studies.
The purpose of this study was to evaluate the effects of the 'off-label' use of ivabradine in patients with CS complicating a ST-elevation AMI.
Methods

Study Protocol
In the clinical setting of a cardiac intensive care unit (CICU), from September 2012 to December 2014 consecutive patients with CS complicating an AMI were randomly assigned to two treatment groups in this randomized open-label prospective study: standard treatment and standard treatment plus ivabradine. Eligible patients were assigned to the two treatment groups according to a computer-generated list of randomisation. Informed consent was obtained from all individual participants included in the study.
Patients were eligible for participation in the study if they had: AMI complicated by CS, LV ejection fraction (LVEF) \40 %, sinus rhythm with HR C75 beats/min, systolic blood pressure (SBP) B100 mmHg that contraindicates treatment with BBs. Exclusion criteria were atrial fibrillation and II-III degree atrioventricular block.
Prior to randomisation, all the patients underwent primary percutaneous coronary revascularisation with stenting of the diseased vessel before being transferred to the CICU. Significant coronary lesions in other vessels were also treated in the same session. No patient had evidence of instent thrombosis after the procedure.
Standard treatment included intravenous sympathomimetic inotropic drugs (dopamine, dobutamine, epinephrine or norepinephrine, as needed) and use of intraaortic balloon pump in all patients. BBs and angiotensin converting enzyme (ACE)-inhibitors were not administered because of the haemodynamic instability of the clinical picture during hospitalisation and in the first month of follow-up. All the patients received double antiplatelet treatment (aspirin plus an adenosine diphosphate (ADP) receptor inhibitor) and heparin.
Patients in the ivabradine treatment group received the study drug in addition to standard therapy at a starting dose of 2.5 mg twice daily. The dose was titrated throughout the study (during hospitalisation and after discharge, when needed) to 5 or 7.5 mg twice daily according to resting HR and tolerability.
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki Declaration and Good Clinical Practice and was approved by the local ethics committee. All patients provided written informed consent prior to study participation.
Patients were followed up for a period of 6 months or until the following CV events occurred: atrial fibrillation, atrioventricular blocks, re-infarction or death.
Due to the experimental character of this study, the halving of the N-terminal fragment of the B-type natriuretic peptide (NT-proBNP, measured at 1 week of treatment), which is a useful diagnostic and prognostic biomarker of heart failure [12] , was chosen as surrogate primary end-point and for sample size calculation.
The secondary end-points were cardiovascular death, hospital re-admission for worsening heart failure, and clinical and haemodynamic improvement.
Clinical, Haemodynamic and Echocardiographic Monitoring
Clinical (New York Heart Association (NYHA) functional class) and haemodynamic parameters (BP and HR) and the N-terminal fragment of the B-type natriuretic peptide (NTproBNP) values were monitored at times T0 (admission), T1 (1 week), T2 (1 month), T3 (3 months) and T4 (6 months) from the onset of AMI. LVEF and LV diastolic function (LVDF) were evaluated at T0 and T3. NT-proBNP was measured in venous blood by the AxSYM immunoenzymatic assay (Abbott Laboratories, Dundee, UK).
LVEF and LVDF were evaluated by transthoracic echocardiography using a phased-array imaging system equipped with a transducer with second harmonics capability. The same technician, under blind conditions, using the same technique and the same equipment obtained the two recordings at T0 and T3. Images were obtained in the parasternal long-and short-axis and apical views, with the subject recumbent in the left lateral position.
All measurements were taken according to the recommendations of the American Society of Echocardiography and the European Association of Echocardiography [13] .
LVDF was classified as normal (Grade 1), impaired LV relaxation (Grade 2), pseudo-normal (Grade 3) or restrictive (Grade 4), based on standard criteria.
All patients were carefully monitored to assess the safety and tolerability of ivabradine administration. The following adverse events were noted: excessive bradycardia (HR \50/min), II-III degree atrioventricular block and atrial fibrillation.
Statistical Analysis
The sample size was determined with G*power program (version 3.1.9.2) [14] . Based on the Mann-Whitney U test, considering an additional reduction due to ivabradine on NT-proBNP (one tail) at T1 of 16.7 % (from an expected reduction of 33.3 % in control patients to a target reduction of 50 % in ivabradine-treated patients), one-tailed a = 0.05, power (1 -b) = 0.80 with an allocation ratio 1:1, 30 patients for each group (60 patients in total), were needed.
Categorical data were presented as absolute frequencies and percent values. Quantitative measurements were expressed as mean ± SD.
Data were checked for normality of distribution (Shapiro-Wilks test) and homogeneity of variances (Levene test) in the overall group of patients as well as in the two groups of patients separately.
Due to non-normality of data and/or dishomogeneity of variance for some variables, the clinical characteristics of the two groups of patients were compared by Fisher's exact probability test (in case of two-by-two contingency tables) or by the chi-squared test for categorical data and the Mann-Whitney U test for quantitative variables.
Differences between the two treatment groups with respect to SBP, diastolic BP (DBP), HR, LVEF and NTproBNP were analysed by means of non-parametric ANOVA. Specifically, for any outcome the following additional variables were computed within each patient: the sum of all observations collected at different times from T0 to T4 (SUM); the differences between the observations at each time after T0 and the observation at T0 (DIFF10, DIFF20, DIFF30, DIFF40). The following analyses were then performed: (1) Friedman's ANOVA in the overall group of patients to evaluate differences across time (i.e. main effect of time); (2) Kruskal-Wallis ANOVA on SUM to evaluate differences between treatments (i.e. main effect of treatment); (3) Kruskal-Wallis ANOVA on DIFF10, DIFF20, DIFF30 and DIFF40, to evaluate the interaction time-by-treatment.
Multiple comparisons for quantitative data were performed: (1) within groups using Wilcoxon's test and, (2) between groups by the Mann-Whitney U test. For categorical matched-pair data (LVDF), McNemar's test was performed to assess the significance of the difference between two correlated proportions.
Bonferroni's correction was applied to control the experiment-wise type I error probability. The alternative hypothesis was postulated as bidirectional for all the analyses. A p value of B0.05 was considered statistically significant.
Statistical analysis was performed using a BMDP package (release 7.0, Berkeley, CA, USA).
Results
Of the 60 randomized patients (see Sect. 2.3), 58 were enrolled due to the onset of atrial fibrillation in two patients before the beginning of the trial: 28 in the standard treatment group and 30 in the ivabradine treatment group.
Twenty-two patients needed orotracheal intubation (OTI): 11 were randomized to the standard treatment group and 11 to the ivabradine group. In the occurrence of OTI, ivabradine or other oral medications were administered by nasogastric intubation.
Low-dose (\50 % of target BP and HR) BBs and ACEinhibitors were administered from the second month of follow-up until the end of the study in patients in both treatment groups when needed (HR [75/min, SBP[110 mmHg). In particular, BBs were administered in 18/24 patients (75 %) in the standard treatment group and in 18/28 patients (64.3 %) in the ivabradine treatment Values are expressed as mean ± SD or n (%)
FH family history of cardiovascular disease, CA carotid atherosclerosis, CRF chronic renal failure, AMI acute myocardial infarction, OTI orotracheal intubation a Quantitative variables refer to the Mann-Whitney U test, categorical variables to Fisher's exact probability test (in case of two-by-two contingency tables) or to the chi-squared test group, but there was no statistical difference between groups. ACE-inhibitors were administered in 20/24 patients (83 %) of the standard treatment group and in 23/28 patients (82.1 %) of the ivabradine treatment group, but there was no statistical difference between groups. The two groups were statistically similar with regard to age, gender distribution, presence of CV risk factors (hypertension, smoking, diabetes, dyslipidaemia, family history of CV disease, carotid atherosclerosis and chronic renal failure), number of diseased vessels and overall treated lesions, AMI site and occurrence of OTI. In-hospital mortality was double in the standard treatment group in comparison with the ivabradine treatment group (four vs. two), but the difference was not statistically significant (Table 1 ). There were no deaths, no re-infarctions, no lifethreatening arrhythmias or II-III degree atrioventricular blocks, or hospital re-admission for worsening heart failure in either group in the 6 months of follow-up. No patient was lost to follow-up.
HR significantly and progressively decreased throughout follow-up in both groups, but the reduction was significantly higher at T2, T3 and T4 in the ivabradine treatment group (Tables 2, 3) .
Both SBP and DBP progressively increased in both groups, but the increase was significantly greater in the ivabradine treatment group at all times but T1 for DBP (Tables 2, 3) .
LVEF (significantly lower at T0 in the ivabradine treatment group) increased in both groups at T3, but the magnitude of the increase was significantly greater in the ivabradine treatment group, so that LVEF values were similar in the two groups at T3 (Tables 2, 3 ).
At T0, 14 patients (46.7 %) in the ivabradine treatment group and eight (28.6 %) in the standard treatment group had Grade 3 diastolic dysfunction (p = not significant, NS). At T3, LVDF significantly changed only in the ivabradine treatment group: 10 out of 14 patients with Grade 3 diastolic dysfunction improved to Grades 1-2 The early halving of NT-proBNP, which was chosen as a surrogate primary end-point, was met. NT-proBNP significantly and progressively decreased throughout followup in both groups, but the reduction was significantly higher at T3 and T4 in the ivabradine treatment group at T1 (Tables 2, 3) .
The group of patients treated with ivabradine did not experience adverse events during the in-hospital stay or during follow-up.
Discussion
This was the first open-label randomized study on the use of ivabradine in CS complicating ST elevation AMI. Moreover, it is the only study in CS where the possible beneficial effects of this drug on LV systolic and diastolic function were objectively monitored by means of echocardiography.
In this small prospective trial the administration of ivabradine on top of the standard treatment including inotropic drugs and intra-aortic balloon pump was able to improve the clinical and haemodynamic picture throughout a follow-up period of 6 months, even if the in-hospital mortality reduction was not statistically significant. These benefits were objectivised by favourable modifications of the echocardiographic parameters and the NT-proBNP assays. In particular, the reversal of cardiac remodeling with ivabradine mirrored similar results obtained by Tardif et al. [15] . In addition, the beneficial haemodynamic effects we obtained in our patients could be attributed to the improvement of the inotropic action of the sympathomimetic drugs, favoured by the HR-lowering capability of ivabradine, as demonstrated by Gallet et al. [16] .
In a previous non-randomized report [11] , 10 patients with acute decompensated systolic HF were experimentally administered ivabradine, but they were not in critical clinical conditions (e.g. hypotension requiring inotropic drugs, OTI) as our patients. However, even in this setting, ivabradine administration improved the clinical and haemodynamic parameters and NT-proBNP decreased.
On the basis of these limited sample-size observations, but also because of the disappointing results of the SIG-NIFY trial [17] , it can be assumed that the HR-lowering effect of ivabradine administration is beneficial, in terms of significant outcomes, in clinical syndromes where a depressed LV function activates a neurohormonal response with consequent HR increase.
Conclusion
In conclusion, in this small randomized open-label study, we were able to demonstrate that titrated-dose administration of ivabradine in CS complicating ST-elevation AMI is safe and is associated with short-term favourable outcomes. We suggest that ivabradine is an alternative HRlowering option in AHF, when BBs are contraindicated, and can be effectively administered by nasogastric intubation in the presence of OTI.
